A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older
The 23-valent capsular polysaccharide pneumococcal vaccine (PPSV23) was introduced in Japan’s routine immunization schedule October 2014. It was recommended for adults aged 65 years (including those ≥65 during the transition period), and for adults 60–64 with cardiac, renal, or respiratory dysfuncti...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-07-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2019.1690332 |
| _version_ | 1827809599475941376 |
|---|---|
| author | Kenji Kawakami Atsushi Nakamura Akira Wakana Temitope A. Folaranmi Tomoharu Iino |
| author_facet | Kenji Kawakami Atsushi Nakamura Akira Wakana Temitope A. Folaranmi Tomoharu Iino |
| author_sort | Kenji Kawakami |
| collection | DOAJ |
| description | The 23-valent capsular polysaccharide pneumococcal vaccine (PPSV23) was introduced in Japan’s routine immunization schedule October 2014. It was recommended for adults aged 65 years (including those ≥65 during the transition period), and for adults 60–64 with cardiac, renal, or respiratory dysfunction equivalent to Level 1 physical disability. Several studies have shown that patients aged 50+ with chronic medical conditions (CMC) are at elevated risk of pneumococcal infection. Nonetheless, PPSV23 vaccination rates among this population remains low. In our study, we report the results of a survey investigation into PPSV23 vaccination rates among Japanese patients aged 50+ with CMC. Patients aged 50+ comprised the patient population (n = 5,078) and internal medicine physicians comprised the doctor population (n = 400) located all over Japan were asked an array of questions relevant to PPSV23 immunization in June 2018 via Web-based surveys. PPSV23 coverages among chronic patients aged 50–59, 60–64, and 65+ years were respectively 1.3%, 2.9%, and 37.8%. The high disease-specific PPSV23 rates seen in the 65+ group was 50.0% and 49.4%, for chronic liver disease and chronic lung disease, respectively. Doctors most frequently cited a lack of municipal subsidies as justification for recommending the vaccine to patients with CMC aged 50–64 years, and deference to patients’ wishes as justification for patients with CMC aged 65+. In conclusion, PPSV23 has poor coverage among Japanese adults aged 50–64 with CMC. Doctors and local authorities need to raise public awareness to improve the vaccination rate, given the high risk of pneumococcal infectious disease among patients with CMC. |
| first_indexed | 2024-03-11T22:43:45Z |
| format | Article |
| id | doaj.art-7540768076314a9b9512b377f5f430a9 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:43:45Z |
| publishDate | 2020-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-7540768076314a9b9512b377f5f430a92023-09-22T08:45:34ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2020-07-011671521152810.1080/21645515.2019.16903321690332A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and olderKenji Kawakami0Atsushi Nakamura1Akira Wakana2Temitope A. Folaranmi3Tomoharu Iino4NTT East Izu HospitalMSD K.KMSD K.KMerck & Co., IncMSD K.KThe 23-valent capsular polysaccharide pneumococcal vaccine (PPSV23) was introduced in Japan’s routine immunization schedule October 2014. It was recommended for adults aged 65 years (including those ≥65 during the transition period), and for adults 60–64 with cardiac, renal, or respiratory dysfunction equivalent to Level 1 physical disability. Several studies have shown that patients aged 50+ with chronic medical conditions (CMC) are at elevated risk of pneumococcal infection. Nonetheless, PPSV23 vaccination rates among this population remains low. In our study, we report the results of a survey investigation into PPSV23 vaccination rates among Japanese patients aged 50+ with CMC. Patients aged 50+ comprised the patient population (n = 5,078) and internal medicine physicians comprised the doctor population (n = 400) located all over Japan were asked an array of questions relevant to PPSV23 immunization in June 2018 via Web-based surveys. PPSV23 coverages among chronic patients aged 50–59, 60–64, and 65+ years were respectively 1.3%, 2.9%, and 37.8%. The high disease-specific PPSV23 rates seen in the 65+ group was 50.0% and 49.4%, for chronic liver disease and chronic lung disease, respectively. Doctors most frequently cited a lack of municipal subsidies as justification for recommending the vaccine to patients with CMC aged 50–64 years, and deference to patients’ wishes as justification for patients with CMC aged 65+. In conclusion, PPSV23 has poor coverage among Japanese adults aged 50–64 with CMC. Doctors and local authorities need to raise public awareness to improve the vaccination rate, given the high risk of pneumococcal infectious disease among patients with CMC.http://dx.doi.org/10.1080/21645515.2019.169033223-valent pneumococcal capsular polysaccharide vaccine (ppsv23)vaccination coveragenationwide surveychronic medical conditioncross-sectional study |
| spellingShingle | Kenji Kawakami Atsushi Nakamura Akira Wakana Temitope A. Folaranmi Tomoharu Iino A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older Human Vaccines & Immunotherapeutics 23-valent pneumococcal capsular polysaccharide vaccine (ppsv23) vaccination coverage nationwide survey chronic medical condition cross-sectional study |
| title | A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older |
| title_full | A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older |
| title_fullStr | A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older |
| title_full_unstemmed | A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older |
| title_short | A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older |
| title_sort | japanese nationwide survey of 23 valent pneumococcal capsular polysaccharide vaccine ppsv23 coverage among patients with chronic medical condition aged 50 and older |
| topic | 23-valent pneumococcal capsular polysaccharide vaccine (ppsv23) vaccination coverage nationwide survey chronic medical condition cross-sectional study |
| url | http://dx.doi.org/10.1080/21645515.2019.1690332 |
| work_keys_str_mv | AT kenjikawakami ajapanesenationwidesurveyof23valentpneumococcalcapsularpolysaccharidevaccineppsv23coverageamongpatientswithchronicmedicalconditionaged50andolder AT atsushinakamura ajapanesenationwidesurveyof23valentpneumococcalcapsularpolysaccharidevaccineppsv23coverageamongpatientswithchronicmedicalconditionaged50andolder AT akirawakana ajapanesenationwidesurveyof23valentpneumococcalcapsularpolysaccharidevaccineppsv23coverageamongpatientswithchronicmedicalconditionaged50andolder AT temitopeafolaranmi ajapanesenationwidesurveyof23valentpneumococcalcapsularpolysaccharidevaccineppsv23coverageamongpatientswithchronicmedicalconditionaged50andolder AT tomoharuiino ajapanesenationwidesurveyof23valentpneumococcalcapsularpolysaccharidevaccineppsv23coverageamongpatientswithchronicmedicalconditionaged50andolder AT kenjikawakami japanesenationwidesurveyof23valentpneumococcalcapsularpolysaccharidevaccineppsv23coverageamongpatientswithchronicmedicalconditionaged50andolder AT atsushinakamura japanesenationwidesurveyof23valentpneumococcalcapsularpolysaccharidevaccineppsv23coverageamongpatientswithchronicmedicalconditionaged50andolder AT akirawakana japanesenationwidesurveyof23valentpneumococcalcapsularpolysaccharidevaccineppsv23coverageamongpatientswithchronicmedicalconditionaged50andolder AT temitopeafolaranmi japanesenationwidesurveyof23valentpneumococcalcapsularpolysaccharidevaccineppsv23coverageamongpatientswithchronicmedicalconditionaged50andolder AT tomoharuiino japanesenationwidesurveyof23valentpneumococcalcapsularpolysaccharidevaccineppsv23coverageamongpatientswithchronicmedicalconditionaged50andolder |